94 related articles for article (PubMed ID: 24613008)
1. Gender differences in HIV infection: is there a problem? Analysis from the SCOLTA cohorts.
Menzaghi B; Ricci E; Vichi F; De Sociod GV; Carenzi L; Martinelli C; Franzetti M; Orofino G; Madeddu G; Parruti G; Penco G; Grosso C; Di Biagio A; Bonfanti P; Quirino T;
Biomed Pharmacother; 2014 Apr; 68(3):385-90. PubMed ID: 24613008
[TBL] [Abstract][Full Text] [Related]
2. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).
Menzaghi B; Ricci E; Carenzi L; Parruti G; Orofino G; Guastavigna M; Madeddu G; Maggi P; Di Biagio A; Corsi P; Penco G; De Socio G; Martinelli C; Vichi F; Celesia BM; Franzetti M; Grosso C; Molteni C; Bonfanti P; Quirino T
Biomed Pharmacother; 2013 May; 67(4):293-8. PubMed ID: 23433852
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
[TBL] [Abstract][Full Text] [Related]
5. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
Madeddu G; De Socio GV; Ricci E; Quirino T; Orofino G; Carenzi L; Franzetti M; Parruti G; Martinelli C; Vichi F; Penco G; Dentone C; Celesia BM; Maggi P; Libertone R; Bagella P; Di Biagio A; Bonfanti P;
Int J Antimicrob Agents; 2015 Mar; 45(3):289-94. PubMed ID: 25476452
[TBL] [Abstract][Full Text] [Related]
6. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
7. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
[TBL] [Abstract][Full Text] [Related]
12. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.
Bonfanti P; Martinelli C; Ricci E; Carradori S; Parruti G; Armignacco O; Magnani C; Quirino T;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):317-20. PubMed ID: 15980692
[TBL] [Abstract][Full Text] [Related]
13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
14. Relevant gender differences in epidemiological profile, exposure to first antiretroviral regimen and survival in the Spanish AIDS Research Network Cohort.
Pérez-Elías MJ; Muriel A; Moreno A; Martinez-Colubi M; Iribarren JA; Masiá M; Blanco JR; Palacios R; Del Romero J; Pérez DG; Hernando V;
Antivir Ther; 2014; 19(4):375-85. PubMed ID: 24304821
[TBL] [Abstract][Full Text] [Related]
15. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
16. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
[TBL] [Abstract][Full Text] [Related]
17. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
Taramasso L; Madeddu G; Ricci E; De Socio GV; Menzaghi B; Orofino G; Passerini S; Franzetti M; Maggi P; Dentone C; Martinelli C; Celesia BM; Penco G; Libertone R; Quirino T; Bonfanti P; Di Biagio A;
Biomed Pharmacother; 2015 Feb; 69():233-6. PubMed ID: 25661363
[TBL] [Abstract][Full Text] [Related]
19. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
